The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 38, No. 1, pp. 86-90. DOI 10.1345/aph.1D144
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eiland, L. S
Right arrow Articles by Guest, A. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eiland, L. S
Right arrow Articles by Guest, A. L

NEW DRUG APPROVALS

Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder

Lea S Eiland, PharmD

Assistant Clinical Professor of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Huntsville, AL

Abby L Guest

PharmD Student, Harrison School of Pharmacy, Auburn University

Reprints: Lea S Eiland PharmD, UAB/Division of Pediatrics, 301 Governors Dr., Huntsville, AL 35801-5123, fax 256/551-4453, eilanls{at}auburn.edu

OBJECTIVE: To review the literature of the first nonstimulant approved for treatment of attention-deficit/hyperactivity disorder (ADHD).

DATA SOURCES: Primary literature and review articles were obtained through PubMed/MEDLINE (1966–February 2003).

STUDY SELECTION AND DATA EXTRACTION: Literature evaluating atomoxetine in ADHD was selected. Animal data were excluded.

DATA SYNTHESIS: Stimulants are currently first-line therapy for ADHD. However, their use raises several concerns including the potential for abuse and adverse effects. Atomoxetine introduces a new therapeutic drug class, selective norepinephrine-reuptake inhibitors, for ADHD management. This additional treatment option offers potential advantages over current therapies.

CONCLUSIONS: Clinical trials demonstrate that atomoxetine is a safe and effective alternative for ADHD treatment in children and adults; however, its disadvantages may hinder it from becoming a first-line agent.

Key Words: atomoxetine, attention-deficit/hyperactivity disorder

Published Online, December 5, 2003. www.theannals.com, DOI 10.1345/aph.1D144

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-002-H01


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
H. Mulder, E. R Heerdink, E. E van Iersel, F. W Wilmink, and A. C. Egberts
Prevalence of Patients Using Drugs Metabolized by Cytochrome P450 2D6 in Different Populations: a Cross-Sectional Study
Ann. Pharmacother., March 1, 2007; 41(3): 408 - 413.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.